SCHEMBL5539478

SCHEMBL5539478

O=CCCCCCc1ccc(Cl)c(Cl)c1

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
IGF1R P08069 1/20 0.54
ALOX15 P16050 1/20 0.54
SIGMAR1 Q99720 11/20 0.49
PNMT P11086 1/20 0.48
TAAR1 Q96RJ0 1/20 0.48
PYGL P06737 1/20 0.46
HDAC6 Q9UBN7 1/20 0.43
IDO1 P14902 1/20 0.42
CDK1 P06493 1/20 0.42
MEN1 O00255 1/20 0.40
ALDH1A1 P00352 1/20 0.40
TP53 P04637 1/20 0.40
CYP1A2 P05177 1/20 0.40
MAPT P10636 1/20 0.40
CYP2C19 P33261 1/20 0.40
KMT2A Q03164 1/20 0.40
PDPK1 O15530 1/20 0.40
TRPV1 Q8NER1 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545868 0.98 IGF1R (0.56) IGF1RALOX15SIGMAR1PNMTTAAR1
SCHEMBL5544409 0.93 IGF1R (0.53) IGF1RALOX15SIGMAR1PNMTTAAR1
SCHEMBL1150953 0.85 PNMT (0.55) IGF1RALOX15SIGMAR1PNMTTAAR1
SCHEMBL11199961 0.81 CBS (0.39) IGF1RALOX15CDK1ALDH1A1TRPV1
SCHEMBL11069977 0.81 PPARA (0.48) IGF1RALOX15PYGLCDK1MEN1
SCHEMBL10898569 0.81 KAT8 (0.48) IGF1RALOX15PYGLCDK1MEN1
SCHEMBL10610096 0.79 IGF1R (0.59) IGF1RALOX15SIGMAR1PNMTTAAR1
SCHEMBL8905774 0.79 IGF1R (0.59) IGF1RALOX15SIGMAR1PNMTTAAR1
SCHEMBL10609249 0.79 IGF1R (0.59) IGF1RALOX15SIGMAR1PNMTTAAR1
SCHEMBL5547783 0.79 HDAC3 (0.47) IGF1RALOX15TAAR1HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 IGF1R 459/4885ALOX15 2847/4885SIGMAR1 234/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.